Hikma Bows To US Korlym IP With 2034 Settlement Deal
Teva Hatch-Waxman Case Remains Active, If Not Cold, In New Jersey Court
Hikma has opted to settle near two-year old patent-infringement litigation with Corcept Therapeutics over its breakthrough treatment for endogenous Cushing’s syndrome, Korlym.
